In BRAFV600E inhibitors (BRAFi)-resistant melanomas, the addition of MDSC depletion/blockade (anti-Gr-1 + CCR2 antagonist) prevented outgrowth of BRAFi-resistant tumors, although combination checkpoint blockade (anti-CTLA-4 + anti-PD-1) was ineffective (82). The gene discussed is CTLA4; the disease is melanoma.